Cargando…

Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients

PURPOSE: We estimated the expression of nuclear factor kappa B/p65 in non-germinal center B-cell-like subtype diffuse large B-cell lymphoma, to investigate its relationship to clinicopathological features, and to further evaluate its prognostic value and clarify its impact on survival. RESULTS: Amon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jing, Zhou, Min, Zhang, Qi-Guo, Xu, Jingyan, Lin, Tong, Zhou, Rong-Fu, Li, Juan, Yang, Yong-Gong, Chen, Bing, Ouyang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354765/ https://www.ncbi.nlm.nih.gov/pubmed/28039454 http://dx.doi.org/10.18632/oncotarget.14182

Ejemplares similares

Primary Cutaneous DLBCL Non-GCB Type: Challenges of a Rare Case
por: Sica, Antonello, et al.
Publicado: (2020)

Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement
por: Geng, Hongzhi, et al.
Publicado: (2023)

Targeting PIN-1 Attenuates GCB DLBCL Cell Proliferation Through Inhibition of PI3K/AKT Signaling
por: Yang, Haijun, et al.
Publicado: (2020)

GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner
por: Xia, Zhizhou, et al.
Publicado: (2021)

P1196: ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R-CHOP-LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON-GCB DLBCL
por: Qu, Chang-Ju, et al.
Publicado: (2023)

P1185: ANTITUMOR ACTIVITY AND SAFETY OF ZANUBRUTINIB COMBINED WITH R-CHOP REGIMEN IN THE TREATMENT OF NEWLY DIAGNOSED NON-GCB DLBCL WITH EXTRANODAL INVOLVEMENT: A PROSPECTIVE PHASE II STUDY.
por: Li, C., et al.
Publicado: (2022)

P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)
por: Zhu, H., et al.
Publicado: (2022)

Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker
por: Batlle-López, Ana, et al.
Publicado: (2016)

Increased expression of nuclear factor kappa-B p65 subunit in adenomyosis
por: Park, Hana, et al.
Publicado: (2016)

P1190: EFFICACY AND SAFETY OF SELINEXOR COMBINING WITH R-CHOP IN THE TREATMENT OF NEWLY DIAGNOSED HIGH RISK (IPI 3-5) GCB SUBTYPE DLBCL PATIENTS: A MULTICENTER RETROSPECTIVE REAL-WORLD STUDY FROM CHINA.
por: Zhi-Ming, LI, et al.
Publicado: (2023)

A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas
por: van der Meeren, L. E., et al.
Publicado: (2019)

Germinal Center B Cell-Like (GCB) and Activated B Cell-Like (ABC) Type of Diffuse Large B Cell Lymphoma (DLBCL): Analysis of Molecular Predictors, Signatures, Cell Cycle State and Patient Survival
por: Blenk, S., et al.
Publicado: (2007)

Intranuclear Delivery of Nuclear Factor-Kappa B p65 in a Rat Model of Tooth Replantation
por: Kang, Chung-Min, et al.
Publicado: (2021)

Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma
por: Boltežar, Lučka, et al.
Publicado: (2018)

The Immunology of DLBCL
por: Takahara, Taishi, et al.
Publicado: (2023)

Sir Alfred Keogh, G.C.B., M.D.: The Director-General of the Army Medical Service
Publicado: (1917)

Sir Alfred Keogh, G.C.B. M.D.: Rector of the Imperial College of Science and Technology
Publicado: (1918)

Epstein–Barr virus infection is associated with the nuclear factor-kappa B p65 signaling pathway in renal cell carcinoma
por: Farhadi, Ali, et al.
Publicado: (2022)

Identification of FAT4 as a positive prognostic biomarker in DLBCL by comprehensive genomic analysis
por: Lv, Liyang, et al.
Publicado: (2023)

Prognostic role of pretreatment neutrophil-lymphocyte ratio in patients with diffuse large B-cell lymphoma treated with RCHOP
por: Wang, Jing, et al.
Publicado: (2016)

Check'-ing DLBCL
por: Salaverria, Itziar, et al.
Publicado: (2015)

DLBCL Coast to Coast
por: Tesio, Melania
Publicado: (2018)

GOALs in relapsed DLBCL
por: Rösler, Wiebke, et al.
Publicado: (2022)

IQGAP2 acts as an independent prognostic factor and is related to immunosuppression in DLBCL
por: Tang, Tianjiao, et al.
Publicado: (2021)

TDP-43 Inhibits NF-κB Activity by Blocking p65 Nuclear Translocation
por: Zhu, Jingyan, et al.
Publicado: (2015)

KDM3A Inhibition Ameliorates Hyperglycemia-Mediated Myocardial Injury by Epigenetic Modulation of Nuclear Factor Kappa-B/P65
por: Zhang, Bofang, et al.
Publicado: (2022)

P1191: A NOVEL PROGNOSTIC MODEL OF DLBCL PATIENTS BASED ON CUPROPTOSIS RELATED GENES
por: Fu, LI, et al.
Publicado: (2023)

Binding of NF-kappaB p65 subunit to the promoter elements is involved in LPS-induced transactivation of miRNA genes in human biliary epithelial cells
por: Zhou, Rui, et al.
Publicado: (2010)

Corrigendum: KDM3A inhibition ameliorates hyperglycemia-mediated myocardial injury by epigenetic modulation of nuclear factor kappa-B/P65
por: Zhang, Bofang, et al.
Publicado: (2023)

Prognostic analysis of DLBCL patients and the role of upfront ASCT in high-intermediate and high-risk patients
por: Zhao, Ying, et al.
Publicado: (2017)

NF-kappaB p65-Dependent Transactivation of miRNA Genes following Cryptosporidium parvum Infection Stimulates Epithelial Cell Immune Responses
por: Zhou, Rui, et al.
Publicado: (2009)

P1188: DYNAMIC CHANGES IN CIRCULATING EBV-DNA LOAD DURING TREATMENT HAVE PROGNOSTIC VALUES IN EBV+ DLBCL-NOS: A CHINESE COHORT STUDY
por: Xing, Tong-Yao, et al.
Publicado: (2023)

Adiponectin inhibits the activation of lung fibroblasts and pulmonary fibrosis by regulating the nuclear factor kappa B (NF-κB) pathway
por: Wang, Xin, et al.
Publicado: (2022)

Pretreatment Liver Injury Predicts Poor Prognosis of DLBCL Patients
por: Shi, Qing, et al.
Publicado: (2017)

Vitamin D3 inhibits lipopolysaccharide-induced placental inflammation through reinforcing interaction between vitamin D receptor and nuclear factor kappa B p65 subunit
por: Chen, Yuan-Hua, et al.
Publicado: (2015)

Human β-defensin-3 and nuclear factor-kappa B p65 synergistically promote the cell proliferation and invasion of oral squamous cell carcinoma
por: Du, Yongxiu, et al.
Publicado: (2022)

Morris Water Maze Training in Mice Elevates Hippocampal Levels of Transcription Factors Nuclear Factor (Erythroid-derived 2)-like 2 and Nuclear Factor Kappa B p65
por: Snow, Wanda M., et al.
Publicado: (2015)

Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
por: Hawkes, Eliza A., et al.
Publicado: (2021)

DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set
por: Vrabac, Damir, et al.
Publicado: (2021)

Predictive Value of Interim PET/CT in DLBCL Treated with R-CHOP: Meta-Analysis
por: Sun, Na, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_69vg2iqg2avu6e4s5l73llrldf